News

Year: 
2010 | 2009 | 2008 | 2007 | 2006
5/21/2010 Pharming Receives D180 List Of Outstanding Issues On Rhucin MAA
4/20/2010 Dyax Corp. Sells Rights to Xyntha(R) Royalty Stream to Paul Capital Healthcare for up to $12 Million
4/15/2010 Swedish Orphan Biovitrum And Pharming Sign Rhucin® Distribution Agreement
4/1/2010 Pharming’s C1 Inhibitor Effective In Preventing AMR In Animal Model Of Transplant Rejection
3/18/2010 Pharming Submits Response To Questions MAA Rhucin
3/4/2010 SpePharm announces the acquisition of Savene® from TopoTarget
2/17/2010 Pharming’s C1 Inhibitor Product Potentially Effective In Reducing Complications Following Transplantation
2/5/2010 Flutiform US NDA update
1/22/2010 Pharming Gives Update On Rhucin EU Marketing Authorization Application
1/11/2010 A.P. Pharma Receives $2.5 Million Milestone Payment

© 2010 by Paul Capital. All rights reserved.